Asana BioSciences appoints new chief medical officer

BRIDGEWATER, N.J. — Asana BioSciences, a member of the Amneal Alliance of Companies, on Monday announced that it had appointed an oncologist with 20 years’ industry and academic experience as its chief medical officer. Dr. Louis Denis will now oversee the company’s new product candidates and the direction of its strategic development.

“We are extremely pleased with the addition of Dr. Denis, a highly experienced physician and scientist, to our team. It represents a significant step in our evolution as an oncology-focused clinical development company,” Asana president and CEO Sandeep Gupta said.

Most recently, Denis headed up Boehringer Ingelheim’s U.S. medial team for pipeline candidates and strategic partnerships and before that was in leadership roles involveing clinical development and medical affairs at Pfizer. He holds co-inventor status on various patents and has co-authorde more than 30 scientific articles about clinical cancer research.

“I am delighted to join Asana at this transformative time for the company,” Denis said.  “I look forward to working with the Asana team and its scientific advisory board to advance the company's broad portfolio of differentiated targeted therapies to help address major unmet medical needs.”